should not be maintained on the market because in view of the limited evidence of benefit and the risk of serious life-threatening adverse reactions, even at low incidence, the risk/ benefit balance of chlormezanone-containing compounds was considered to be unfavourable. the European Agency for the Evaluation of Medicinal Products has recommended the withdrawal of the Marketing Authorisations of all chlormezanone-containing medicinal products.